Results 91 to 100 of about 15,808 (143)
Many antibiotics originate from soil‐inhabiting Actinobacteria, especially from the diverse genus Streptomyces. However, the emergence of antibiotic resistance poses a significant global challenge to treating infectious diseases. Therefore, the search for Actinobacteria, particularly from less‐explored environments, as potential sources of novel ...
Rajani Balkrishna Rao +6 more
wiley +1 more source
Background Diabetes mellitus and hyperglycemia are associated with increased susceptibility to bacterial infections and poor treatment outcomes. This post hoc evaluation of the treatment of complicated intra-abdominal infections (cIAI) and complicated ...
Myra W. Popejoy +2 more
doaj +1 more source
We tested the in vitro susceptibility of ceftazidime-avibactam and ceftolozane-tazobactam and 13 other antibiotics against 91 Burkholderia cepacia complex (BCC) strains isolated from cystic fibrosis patients since 2012.
Peeters, Charlotte +16 more
core +1 more source
In vitro susceptibility profile of BLEES-positive Enterobacteriaceae isolated from clinical specimens to ceftolozane/tazobactam [PDF]
Las Enterobacterias son un grupo grande y heterogéneo de bacterias gramnegativas, las cuales se caracterizan por su capacidad de producir infecciones en pacientes inmunocompetentes e inmunosuprimidos tanto de la comunidad como en el ambiente ...
Valderrama Rodríguez, Cristian Camilo
core +1 more source
A Novel β-lactam/β-lactamase Inhibitor: Ceftolozane/tazobactam
Ceftolozane/tazobactam is a novel generation cephalosporin and β-lactamase inhibitor combination antibiotic. It was approved for the treatment of adults (18 years and older) with complicated intraabdominal infections used in combination with ...
Kıvanç ŞEREFHANOĞLU
doaj +1 more source
Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC. [PDF]
We compared the dynamics and mechanisms of resistance development to ceftazidime, meropenem, ciprofloxacin, and ceftolozane-tazobactam in wild-type (PAO1) and mutator (PAOMS, ΔmutS) P. aeruginosa.
Moyà, Bartolomé +7 more
core +1 more source
We report the successful use of ceftolozane/tazobactam (C/T) to treat a pulmonary exacerbation in a 35 year old female, post lung transplant, with cystic fibrosis (CF), malnutrition, chronic kidney disease, and multi-drug resistant Pseudomonas aeruginosa
Katie Stokem +4 more
doaj +1 more source
Ceftolozane and tazobactam for the treatment of hospital acquired pneumonia
© 2020, © 2020 Informa UK Limited, trading as Taylor & Francis Group. Introduction: Patients admitted to hospitals are at risk of developing nosocomial infections. These types of infections typically occur in immune compromised patients.
Martin-Loeches I, Bisanti A, Diaz E, Rodriguez A
core
Prevalence of resistance to ceftolozane/tazobactam among Escherichia coli clinical isolates susceptible or resistant to alternative agents.
Brian D. Johnston (580892) +2 more
core +1 more source
Background: Clinical guidelines recommend two novel β-lactam/β-lactamase inhibitor combinations—ceftolozane–tazobactam and ceftazidime–avibactam—as first-line therapies for drug-resistant Pseudomonas aeruginosa infections.
Pengfei Li +3 more
doaj +1 more source

